DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/t8sn38/drg_insight) has announced the addition of Decision Resources, Inc's new report "DRG Insight: Facial Injectables (US)" to their offering.
DRG Insights takes the most relevant information and insights from across our portfolio for BioPharma and Med-Tech products and delivers the insight heavy perspective that you need to generate better ideas and deliver more successful campaigns and initiatives. The North American facial injectable marketcomprising revenues from the sale of botulinum toxin (BTX) and dermal filler products, including hyaluronic acid (HA) dermal fillers, and semi- and nonpermanent non-HA fillers experienced a large decline during the recession, starting in late 2008, but have since experienced a strong recovery.
Through 2016, both the BTX and dermal filler markets will experience high growth as patients continue to demand aesthetic procedures. The entry of Merz Pharmaceutical's Belotero and Xeomin (dermal filler and BTX products, respectively) is altering the competitive landscape because physicians and patients will have a larger range of products to choose from. Competitive pricing pressures, heightened by Merz Pharmaceutical's entry into the market, will limit market growth. Nevertheless, increasing patient aesthetic consciousness and the resultant demand for facial injectable procedures will drive unit sales, thus facilitating the expansion of both the BTX and dermal filler markets.
The US market will continue to account for the majority of facial injectable sales will experience steady and high growth over the forecast period as the number of patients demanding for the treatments continues to rise.
Key Topics Covered:
Introduction to Facial Injectables
Current Market Landscape
End User Insights
Appendix - View of Global Markets
Sources & References
For more information visit http://www.researchandmarkets.com/research/t8sn38/drg_insight
Source: Decision Resources, Inc
Source: Research and Markets